Who are Cattle Encephalon Glycoside and Ignotin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): NeuroAiD, Butylphthalide Soft Capsules, NXY-059, Riluzole (100 mg), Hi-dose iv MgSO4, DMB-I (INN: Latrepirdine).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cattle-encephalon-glycoside-and-ignotin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Cattle Encephalon Glycoside and Ignotin — Competitive Intelligence Brief

Cattle Encephalon Glycoside and Ignotin (Cattle Encephalon Glycoside and Ignotin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neuroprotective agent. Area: Neurology.

phase 3 Neuroprotective agent Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Cattle Encephalon Glycoside and Ignotin (Cattle Encephalon Glycoside and Ignotin) — Rong Hu, MD. Cattle encephalon glycoside and ignotin is a neuroprotective agent derived from bovine brain tissue that enhances neuronal metabolism and cerebral blood flow.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Cattle Encephalon Glycoside and Ignotin TARGET	Cattle Encephalon Glycoside and Ignotin	Rong Hu, MD	phase 3	Neuroprotective agent
NeuroAiD	NeuroAiD	CHIMES Society	marketed	Herbal neuroprotective agent
Butylphthalide Soft Capsules	Butylphthalide Soft Capsules	Peking Union Medical College Hospital	marketed	Neuroprotective agent
NXY-059	NXY-059	AstraZeneca	phase 3	Free radical scavenger / Neuroprotective agent	Reactive oxygen species (ROS) / Free radicals
Riluzole (100 mg)	Riluzole (100 mg)	AB Science	phase 3	Glutamate antagonist / Neuroprotective agent	Glutamate release (presynaptic); voltage-gated sodium channels
Hi-dose iv MgSO4	Hi-dose iv MgSO4	Hamad Medical Corporation	phase 3	NMDA receptor antagonist / Neuroprotective agent	NMDA receptor
DMB-I (INN: Latrepirdine)	DMB-I (INN: Latrepirdine)	Bigespas LTD	phase 3	Neuroprotective agent	NMDA receptor, mitochondrial membrane, monoamine oxidase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neuroprotective agent class)

Bigespas LTD · 1 drug in this class
Capital Medical University · 1 drug in this class
Peking Union Medical College Hospital · 1 drug in this class
Rong Hu, MD · 1 drug in this class
Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cattle Encephalon Glycoside and Ignotin — Competitive Intelligence Brief. https://druglandscape.com/ci/cattle-encephalon-glycoside-and-ignotin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab